Endo International (NASDAQ:ENDP) Stock Rating Upgraded by BidaskClub

Endo International (NASDAQ:ENDP) (TSE:ENL) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Friday, BidAskClub reports.

Several other equities analysts also recently weighed in on ENDP. Royal Bank of Canada restated a “hold” rating and issued a $6.00 target price on shares of Endo International in a research report on Thursday, June 11th. Citigroup initiated coverage on Endo International in a report on Friday, April 24th. They issued a “buy” rating and a $7.00 price objective on the stock. SunTrust Banks reaffirmed a “buy” rating on shares of Endo International in a report on Wednesday, July 8th. Goldman Sachs Group began coverage on shares of Endo International in a research note on Monday, July 27th. They issued a “sell” rating and a $3.00 price target on the stock. Finally, Morgan Stanley lowered their price target on shares of Endo International from $4.00 to $3.00 and set an “underweight” rating on the stock in a research report on Thursday, April 2nd. Four investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Endo International currently has a consensus rating of “Hold” and a consensus price target of $5.43.

ENDP stock opened at $3.48 on Friday. Endo International has a 52-week low of $1.97 and a 52-week high of $7.10. The firm has a market cap of $799.37 million, a P/E ratio of 1.24 and a beta of 1.54. The company’s 50-day simple moving average is $3.46 and its 200-day simple moving average is $4.31.

Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.95 EPS for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.40. Endo International had a negative return on equity of 91.00% and a negative net margin of 9.09%. The business had revenue of $820.40 million during the quarter, compared to analysts’ expectations of $713.62 million. During the same period in the previous year, the business earned $0.60 earnings per share. The business’s revenue was up 13.9% compared to the same quarter last year. On average, research analysts expect that Endo International will post 2.23 EPS for the current year.

A number of hedge funds have recently modified their holdings of ENDP. Hayden Royal LLC acquired a new position in Endo International in the 1st quarter valued at about $54,000. Teza Capital Management LLC purchased a new stake in shares of Endo International during the 1st quarter valued at approximately $61,000. Nisa Investment Advisors LLC raised its position in shares of Endo International by 44.5% during the 1st quarter. Nisa Investment Advisors LLC now owns 29,216 shares of the company’s stock valued at $108,000 after buying an additional 9,000 shares during the period. Acadian Asset Management LLC acquired a new position in Endo International in the first quarter valued at approximately $402,000. Finally, Hunter Associates Investment Management LLC grew its position in Endo International by 8.8% in the first quarter. Hunter Associates Investment Management LLC now owns 111,225 shares of the company’s stock worth $412,000 after acquiring an additional 9,000 shares during the period. 82.29% of the stock is currently owned by institutional investors.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Article: What is the cash asset ratio?

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.